Esomeprazole magnesium salt is a potent and orally active proton pump inhibitor that effectively reduces acid secretion in gastric parietal cells by inhibiting the H+, K+-ATPase. This compound has shown promise for the research and treatment of symptomatic gastroesophageal reflux disease [1][2][3].

Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment inhibits the growth of triple-negative breast cancer cells in vitro by increasing intracellular acidification in a dose-dependent manner [1].

Esomeprazole, administered orally via gavage at doses ranging from 30 to 300 mg/kg daily for either 19 or 11 days, significantly inhibits lung fibrosis progression in C57BL/6J mice. These mice, aged 8 weeks and weighing between 25-30 g, were subjected to cotton smoke-induced lung injury. Additionally, esomeprazole treatment notably reduces circulating markers of inflammation and fibrosis. This study demonstrates esomeprazole's potential efficacy in mitigating pulmonary fibrosis and associated inflammatory markers in this animal model.